The worse long-term outcome observed after percutaneous transluminal coronary angioplasty (PTCA) than after coronary artery bypass grafting (CABG) in patients at high risk of restenosis and disease progression such as diabetics,1–4 remind us that there is a substantial difference.

Significant narrowing or only minor irregularities at the time of the initial treatment.

Arterial grafts, a bypass operation also prevents the acute events due to progression of disease in proximal and mid coronary segments arising from lesions that had no longer for arterial grafts, a bypass operation also prevents the acute events due to progression of disease in proximal and mid coronary segments arising from lesions that had no significant narrowing or only minor irregularities at the time of the initial treatment.

**DRUG COATED STENTS**

Progression of atherosclerosis cannot be addressed even with the best anti-restenotic devices. A drug coated stent may seal a lesion at risk of progression, but it is not reasonable to transform all of the coronary tree into a rigid metal tube to prevent plaque progression, and we still do not have reliable imaging or functional techniques to detect vulnerable plaques. The development of new lipid lowering drugs with high efficacy and low side effects is important since they may improve the long-term outcome of a less invasive combined medical and percutaneous treatment strategy in patients with multivessel disease.5 With multivessel angioplasty these patients are unlikely to enjoy, as after surgery, a honeymoon period of a few years at very low risk of events even if they do not seek proper medical care and have limited adherence to risk factor control. Before treating multivessel disease patients with percutaneous techniques, we must be sure that the patients fully understand the importance of lifestyle changes and accept long-term medical treatment with multiple drugs (antiplatelet and lipid lowering agents) and a programme of regular follow-up visits and investigations.

**COSTS**

With this premise, and if the excellent angiographic result seen at two years after treatment with sirolimus eluting stents is maintained over time, the important step forward in terms of restenosis reduction with the use of drug-eluting stents may justify percutaneous treatment of the majority of patients with multivessel disease. Reimbursement policy and cost of drug-coated stents will also have a big impact on the speed this process will progress. Even if the cost per unit of these devices is reduced by the release of new drug eluting stents and market competition, the complexity of lesions treated must be taken into account by the health care providers to offer reimbursement policies more similar to those offered for surgical procedures in the same patients. In a retrospective review of 273 patients with multivessel disease who underwent bypass surgery at the Royal Brompton Hospital in 2002, percutaneous revascularisation with drug eluting stents was technically feasible in 75% of cases. However, this treatment would have involved lesions for which no data on long-term results with drug eluting stents are available, and its one-year cost would have been similar to the cost of bypass surgery.6 The switch from coronary surgery to interventional cardiology ultimately relies on the capacity of the interventional cardiologists to convince the medical community and health authorities, based on sound data from randomised trials, that percutaneous coronary intervention with drug eluting stents for multivessel disease is feasible, safe, clinically effective, and cost efficient.

Furthermore, it is not enough to increase the number and capacity of our interventional units: we must stop thinking of interventional cardiology as a simple practice every cardiologist can undertake, but instead train dedicated specialists able to cope with the complexity of the new tasks faced.

**REFERENCES**


Silent right ventricular myocardial infarction: the Q wave never lies

T N Martin and H Dargie

*Heart* 2004 90: 1002
doi: 10.1136/hrt.2003.032789

Updated information and services can be found at:
http://heart.bmj.com/content/90/9/1002

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/